GlassScriptPhysician profile
Tayson De Lengocky
NPI 1164637153
$3,883.36
in general payments reported to CMS, 2019-2025
18 companies · $714 in 2025
The $714 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $89.55 · 2021: $411 · 2022: $633 · 2023: $761 · 2024: $1,064 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,538.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $653.22 | 2020-2025 | Cequa |
| Bausch & Lomb Americas INC. | $645.05 | 2024-2025 | Miebo, Vyzulta, Xiidra |
| Abbvie INC. | $540.82 | 2022-2025 | Lumigan, Ozurdex, Alphagan P |
| Oyster Point Pharma, INC. | $412.43 | 2022-2024 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $327.59 | 2023-2025 | Argos, Clareon, Rocklatan |
| Aerie Pharmaceuticals, INC. | $225.16 | 2019-2021 | |
| Horizon Therapeutics Plc | $187.24 | 2021-2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $186.45 | 2021-2024 | Acthar |
| Dompe US, INC. | $167.45 | 2022-2024 | Oxervate |
| Apellis Pharmaceuticals, INC. | $153.41 | 2025 | Syfovre |
| Allergan, INC. | $148.88 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $73.24 | 2024-2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $47.16 | 2024 | Purified Cortrophin Gel |
| Harrow Eye, LLC | $40.64 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $24.15 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $21.11 | 2024 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $15.74 | 2022 | |
| Boston Scientific Corporation | $13.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tayson De Lengocky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.